Poolbeg expands POLB 001 into oncology
Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is…
The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportPoolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is…
Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer,…
A MedUni Vienna research team in Austria has discovered a new highly potent biomarker for…
The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial…
Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU…
A new case of blood cancer gets diagnosed approximately every three minutes in Western countries.…
Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared…
SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed…
The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into…
Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research…
The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022,…
Mission Bio has announced the availability of the Tapestri VCN Assay, the first high-throughput commercial…